<DOC>
	<DOCNO>NCT00795639</DOCNO>
	<brief_summary>This protocol subject pulmonary arterial hypertension first 3 study form Sitaxsentan efficacy safety trial Randomized Prospective Assessment Adding Sildenafil ( SR-PAAS ) program .</brief_summary>
	<brief_title>Sitaxsentan Efficacy And Safety Trial With A Randomized Prospective Assessment Of Adding Sildenafil ( SR-PAAS )</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Hypertension , Pulmonary</mesh_term>
	<mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
	<mesh_term>Endothelin Receptor Antagonists</mesh_term>
	<mesh_term>Sitaxsentan</mesh_term>
	<criteria>Current diagnosis symptomatic pulmonary arterial hypertension ( PAH ) classify one following : idiopathic arterial hypertension ( IPAH ) , primary pulmonary hypertension ( PPH ) , familial pulmonary arterial hypertension ( FPAH ) pulmonary arterial hypertension ( PAH ) associate connective tissue disease . Has WHO functional class III symptom . Previous exposure endothelin receptor antagonist ( ETRA ) sitaxsentan , bosentan ambrisentan .</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Sitaxsentan</keyword>
	<keyword>endothelin receptor antagonist</keyword>
</DOC>